Deep brain stimulation of the internal globus pallidus is associated with improved quality of life and is possibly effective for reducing symptoms of dystonia in X-linked dystonia parkinsonism.
In the Complete Response Letter, the FDA noted that it was unable to approve the application in its present form, however the Agency did not request additional clinical studies.
Investigators examined whether subthalamic nucleus during the use of deep brain stimulation has an effect on risk-reward trade-off decisions, and evaluated its dependency on electrode placement.
Bilateral substantia nigra pars compacta lesion was linked to a memory deficit and to anxiety-like behavior.
Study showed that nabiximols were well tolerated and provided first evidence of efficacy in terms of controlling spasticity in patients with motor neuron disease.
Findings support the efficacy of mexiletine and the potential value of N-of-1 trials for assessing interventions in some chronic rare diseases.
Pharmacologic interventions including oral and injected drugs are a mainstay of spasticity management; however, drug therapies alone are not considered sufficient, and the general consensus supports a broader therapeutic strategy.
The aim of the review was to assess the safety and efficacy of oral and parenteral iron for the treatment of RLS.
For patients with early Parkinson disease, treatment with levodopa combined with carbidopa has no disease-modifying effect.
Investigators observed a wide variety of movement disorders — including restless legs syndrome, tremor, and tonic spasms — associated with early demyelinating diseases.
